CRISPRmod dCas9-VPR or dCas9- SALL1-SDS3 mRNA and synthetic guide RNA transfection protocol
- Clarence Mills 1,2
- 1 - Horizon Team
- 2 - Horizon/Perkin Elmer
Aug 10, 2021
The following is a protocol for transfecting CRISPRmod dCas9-VPR or dCas9-SALL1-SDS3 mRNA with synthetic guide RNA into cultured mammalian cells using DharmaFECT™ Duo transfection reagent (Cat #T-2010-xx). The protocol is written for transfection into 96-well tissue culture plates.
The CRISPR activation (CRISPRa) system is a variation of the canonical CRISPR-Cas9 used for creation of double-strand breaks in genomic DNA. It utilizes a nuclease-deactivated S. pyogenes Cas9 (dCas9), often called "dead Cas9", that is fused to one or more transcriptional activators. When paired with a well-designed guide RNA that targets a gene near a promoter region, the gene's native transcription start site is activated
dCas9-VPR mRNA expresses a human codon-optimized version of the nuclease-deactivated S. pyogenes Cas9 gene, the three transcriptional activators (VP64, p65 and Rta), and two nuclear localization signals (NLS). The dCas9-VPR mRNA is available in a form that co-expresses either EGFP or puromycin for transfection optimization or enrichment using fluorescence-activated cell sorting (FACS) or antibiotic selection.
Reagents and Equipment
DharmaFECT™ Duo transfection reagent (Cat #T-2010-xx)
Time Taken1 hour
ApplicationA Fast and High Precision Influenza Vaccine Potency Assay
ApplicationStrategies for the Development of a High Throughput Octet® Bio-Layer Interferometry Method to Measure Pharmacokinetics of Monoclonal Antibodies in Preclinical Animal Models
MediaGEN Protocols Expert Exchanges: Single-Cell RNA Sequencing--Challenges and Solutions
PrimerNanomembrane Technology Rapidly Isolates Exosomes from Tears
MediaGEN Protocols Expert Exchanges: Nanoparticles in Precision Medicine Diagnostics and Delivery